Performance Share Plan

RNS Number:6831L
Arana Therapeutics Limited
14 January 2008


For Immediate Release                                            14 January 2008


                           Arana Therapeutics Limited

                             Performance share plan


Arana Therapeutics Limited, (AIM: AAHx ASX: AAH) (the "Company"), the Australian
biopharmaceutical company that uses superior technology to develop next
generation drugs that will improve the lives of patients with inflammatory
diseases and cancer has today announced that it had acquired 171,606 shares at a
cost of $199,139 in on-market transactions to fulfil allocations of shares to
certain employees under the rules of the performance share plan.

Arana performed at the 65th percentile in relation to the plan for the period 1
January 2005 to 31 December 2007, resulting in a 78.55% allocation to
participating employees.


About Arana Therapeutics:


Arana Therapeutics (ASX: AAH; AIM: AAHx) is an international biopharmaceutical
company formed through the merger of Peptech and EvoGenix in August 2007. The
company uses superior technology to develop next generation drugs that will
improve the lives of patients with inflammatory diseases and cancer.


Arana Therapeutics' innovative technologies provide the basis for clinical
development in the antibody space, a market which draws on high demand. With a
market capitalisation of around A$250 million and solid cash resources, Arana
Therapeutics has the financial stability and management expertise to accelerate
its clinical programs, and is on track to have at least 3 clinical stage assets
within three years.


Arana is listed on the Australian Securities Exchange (ASX) and the London Stock
Exchange (AIM).


The company's pipeline consists of four lead drug programs: ART621 to treat
severe rheumatoid arthritis and other inflammatory diseases; ART010 to treat
osteoporosis and bone cancer; ART104 to treat solid tumours in colorectal
cancer; and ART150 for lung cancer and melanoma. Additionally, the company has
earlier stage products in development for the treatment of a range of conditions
including age related macular degeneration, psoriasis, colorectal cancer, and
leukaemia.


Arana has recurring revenues from commercial and development partnerships with
six international companies including GSK, CSL, Centocor (J&J) and Abbott
Laboratories.


For further information: www.arana.com



For further information, please contact:

Arana Therapeutics Limited
Dr John Chiplin, Chief Executive Officer             [phone]
Niall Henderson, Chief Financial Officer             [phone]

Buchanan Communication
Lisa Baderoon/Rebecca Skye Dietrich                 [phone]

Nomura Code Securities
Charles Walker                                      [phone]





                      This information is provided by RNS
            The company news service from the London Stock Exchange

END
MSCBIMLTMMABMTP